Maxim Group Reiterates “$8.00” Price Target for Viking Therapeutics (VKTX)

Retrieved on: 2017-12-21 04:15:00

Tags for this article:

Health

Chemistry

LGD-4033

Pyrrolidines

Viking Therapeutics

Click the tags to see associated articles and topics

Maxim Group Reiterates “$8.00” Price Target for Viking Therapeutics (VKTX). View article details on hiswai:

Excerpt

<div>Sphera Funds Management LTD. acquired a new stake in Viking Therapeutics in the third quarter valued at $554,000. <b>Renaissance Technologies</b> LLC lifted its stake in Viking Therapeutics by 62.9% in the first quarter. <b>Renaissance</b> <b>Technologies</b> LLC now owns 265,800 shares of the biotechnology ...</div>

Article found on:

View Original Article